Introduction {#Sec1}
============

African swine fever virus (ASFV) is the causal agent of a haemorrhagic and often-lethal porcine disease, African swine fever (ASF), which causes affected countries important economic losses. There is no vaccine available against the disease, albeit promising developments for future implementation are being currently developed \[[@CR1]\]. ASF may range from an acute, highly lethal infection to subclinical chronic forms, depending on a complex contribution of viral and host factors \[[@CR2]\]. The pig immune response to ASFV has been widely studied \[[@CR3], [@CR4]\], showing that the virus has effective mechanisms of evading pig defensive systems, thus contributing to the immune pathology observed during acute ASF, and to virus persistence in its hosts \[[@CR5]\]. Studies about virus-cells interaction have contributed significantly to unravel the mechanisms involved in pig response \[[@CR3], [@CR6]--[@CR10]\]. In this regard, it has been shown that the ASFV genome encodes a large number of genes that have been identified as playing a role in host immune evasion including: interferon (IFN) inhibition by several multigene family members \[[@CR11]\], the NF-κB and NFAT inhibitor A238L or the apoptosis inhibitor A179L, among others. All these aspects have recently been reviewed \[[@CR12]\]. In addition, it is known that ASFV controls host transcription and cellular machinery of protein synthesis \[[@CR13]\] thus contributing to pathology. The high complexity of ASFV, together with its tropism for the immune system of the host, complicates the understanding of ASF pathogenesis. Both ASFV-specific antibodies \[[@CR4]\] and CD8^+^ T-cells \[[@CR3], [@CR14]\], have been postulated as key players in the protection against ASFV. The dual role of the immune system during ASFV infection becomes evident again during chronic ASF-infections, characterized by mild clinical signs associated, on occasions, with immunopathological processes, such as immune complexes and swine IgM, IgG and C1q depositions \[[@CR15]\]. Swine macrophages are the main target for ASFV, and depending on multiple factors, including the virulence of the ASFV strain, the immune system can play a dual role during both, ASFV-protection but also contributing to the virus pathogenesis. As mentioned above, virulent ASFV strains can evade the early recognition of the immune system, strategies that facilitate their replication and in vivo dissemination that, in the last stages of acute infection, provoke tissue destruction, leukopenia and total dysregulation of the immune system, reflected with the typical storm of cytokines thus contributing to ASF acute pathogenesis \[[@CR16]\]. Conversely, infections with attenuated ASFV strains normally render subclinical infections that are rapidly recognized by the innate immune system and cleared from the body, yielding pigs capable of resisting homologous lethal challenge \[[@CR16]\].

Here we extend these studies by presenting a comparative proteomic analysis using gastrohepatic lymph nodes (GLN) from pigs infected in vivo with either the attenuated E75CV1 strain or with E75, its parental virulent ASFV strain, at different days post-infection (dpi); a model system previously used to unmask some of the mechanisms involved in homologous protection against ASFV \[[@CR16]\]. Since ASFV-infection modifies the expression patterns of host cell proteins, the application of proteomic approaches might help to clarify the intrinsic mechanism involved in ASFV-host interactions, as has been demonstrated \[[@CR10], [@CR17]\]. These methodologies have contributed to better understandings of how some viruses reprogram cell resources for their own benefit, or avoid host defensive mechanisms to survive in their host \[[@CR18]\], but a limited number of proteomic studies have been carried out with swine pathogens. Thus, proteomic strategies have been used to study the differences observed after in vitro infection of Vero cells with virulent or attenuated strains of porcine epidemic diarrhoea virus \[[@CR19]\], or PK-15 cells infected with classical swine fever virus \[[@CR20]\]. Additionally, our group has previously described the protein profile of lymph nodes of piglets inoculated with Porcine circovirus type 2 (PCV2) \[[@CR21]\]. Two proteomic studies have been published so far for ASFV infection: the first one focussed on proteins differentially expressed after ASFV-macrophage infection, although they were not specifically identified \[[@CR17]\] and the second one, using Vero cells infected with the 608VR13 ASFV isolate, identifying proteins involved in apoptosis or in the transcription modulation \[[@CR10]\].

In this work, we have conducted the first 2-DE proteomic approach and bioinformatic data analysis using lymph node tissue from pigs infected with two homologous ASFV strains with distinct virulence: the tissue culture adapted E75CV1, an attenuated virus, and its parental virulent E75 virus. In order to reach a deeper understanding of pig-ASFV interactions and swine immune responses, samples were obtained at different times post-infection. This large- scale proteomic study should provide a complete view of the major and important functions and pathways altered during the infection process, and hopefully, it could be used in the future to develop anti-ASFV strategies.

Materials and methods {#Sec2}
=====================

Experimental design for the in vivo experiment {#Sec3}
----------------------------------------------

The in vivo experiment has been previously described and the animals and samples used in this analysis are the same as those used in experiment 2 of our previous study \[[@CR16]\]. Briefly, a group of 24 pigs was infected with 104 HAU50 of E75CV1, a second group of 18 pigs was infected using the same dose and route of the virulent E75 and finally a third group of 12 pigs remained uninfected (control group). Pigs from the three groups were sacrificed at days 1, 3 and 7 pi (6 or 3 per group and day) and 6 pigs from the attenuated E75CV1 and 3 from the control group were also sacrificed at day 31 pi. Lymph node samples of all animals (54 pigs) were analysed by 2-DE and mass spectrometry (see below).

Two-dimensional gel electrophoresis (2-DE) and image analysis {#Sec4}
-------------------------------------------------------------

GLN were subjected to mechanical dissociation in sample buffer (7 M urea, 2 M thiourea, 4% w/v CHAPS, 1% w/v DTT, 0.8% ampholytes, 0.2 M PMSF) by scraping and gentle squeezing. Each supernatant was recovered and, after clean up precipitation, lymph node protein extracts for each condition (control, E75-infected or E75CV1-infected) and day (1, 3, 7 and 31 dpi) were pooled and analyzed by 2-DE following previously published methods \[[@CR22]\]. Briefly, protein extracts were diluted in rehydration buffer (7 M urea, 2 M thiourea, 4% w/v CHAPS, 20 mM DTT, 0.5% Triton X-100, 0.5% ampholytes) and immobilized pH gradient strips of 17 cm (5--8 linear pH gradient, Bio-Rad) were rehydrated with 300 μL (500 μg) of each protein solution and focused in a PROTEAN IEF Cell (Bio-Rad) using the following parameters: (1) active rehydration at 50 V for 12 h; (2) at 250 V for 15 min without pause after rehydratation; (3) rapid ramp until reaching 10 000 V/h and (4) until 80 000 V/h with slow ramped voltage. Previously, protein profile was analyzed by 2-DE on 3--10 pH gradient strips, finding that the resolved spots were concentrated in the 5--8 pH range. Second dimension was performed on 12% SDS--polyacrylamide gels using PROTEAN PlusTM Dodeca (Bio-Rad). Four replicated for each of the conditions (virulent, attenuated or control) were analyzed simultaneously for each dpi.

Gels were stained with SYPRO Ruby protein gel stain (Bio-Rad). Gel images were digitized with the FX Pro Plus Multi imager system (Bio-Rad) and analyzed with the PD Quest version 7.3 software (Bio-Rad). Spots detected by the program were matched between each gel in each group. Normalized protein spot volume (area multiplied by stain intensity) was calculated for each spot in the control sample and compared to its counterpart (sample from ASFV-infected animals). Intensity data were used to calculate differences in protein expression between groups (controls vs. E75 or E75CV1 infected samples), for each dpi, using a Student's *t* test (*p* \< 0.05) (two-tailed with unequal variances) after checking normality by the Wilks--Shapiro test. Differentially expressed spots were selected for protein identification by mass spectrometry.

Protein identification by mass spectrometry {#Sec5}
-------------------------------------------

Spots were automatically excised in a ProPic station (Genomic Solutions) and digested with modified porcine trypsin (sequencing grade; Promega), by using a ProGest digestion station (Genomic Solutions), as previously described \[[@CR22]\]. Briefly, gel pieces were destained with ammonium bicarbonate/acetonitrile (ACN), and subsequently subjected to dehydration/rehydration cycles and dried. Gel pieces were digested with trypsin, peptides extracted with trichloroacetic acid and desalted and concentrated by using μC-18 ZipTip columns (Millipore) in a ProMS station (Genomic Solutions). After that were loaded onto a 4800 MALDI-TOF/TOF Analyzer (Applied Biosystems) in automatic mode with the following setting: for the Mass Spectrometry (MS) data, m/z range 800--4000 with an accelerating voltage of 20 kV, peak density of maximum 50 peaks per 200 Da, minimal S/N ratio of 10 and maximum peak at 65. Spectra were internally calibrated with peptides from trypsin autolysis (M + H+= 842.509, M + H+= 2211.104). For the MS/MS data, fragment selection criteria were a minimum signal/noise (S/N) ratio of 5, a maximum number of peaks set at 65 and peak density of maximum 50 peaks per 200 Da. For each precursor selected for MS/MS analysis, fragment mass values in the range from 60 to 10 Da below precursor mass were used to peptide identification. Protein identification was assigned by peptide mass fingerprinting and confirmed by MS/MS analysis of at least three peptides in each sample. Mascot 1.9 search engine (Matrixscience) was used for protein identification running on GPS software (Applied Biosystems) against the NCBI mammalian database (updated monthly). Only those proteins with a significant protein score (*p* \< 0.05) according to Mascot were taken into account in subsequent analysis.

Functional analysis of the proteins {#Sec6}
-----------------------------------

Differentially regulated proteins were analyzed through the use of Ingenuity Pathway Analysis software (IPA, Ingenuity^®^ Systems). This system identifies the functions and canonical pathways that are most significant to the data set, supported by canonical information stored in the Ingenuity Knowledge Base. Fisher's exact test was used to calculate a *p* value determining the probability that the association between the proteins in the dataset and the functions and canonical pathways is explained by chance alone. These *p*-values are calculated based on the number of proteins that participate in a given function or pathway relative to the total number of occurrences of proteins in functions or pathway annotations stored in the Ingenuity Pathways Knowledge Base \[[@CR21]\]. The whole Ingenuity Knowledge Base was considered as reference set.

Results {#Sec7}
=======

Two-dimensional electrophoresis reveals differential protein expression kinetics after in vivoinfection with either virulent E75 or attenuated E75CV1 ASFV-isolates {#Sec8}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------

To widen and deepen our understanding of the mechanisms underlying ASFV-pathogenesis and immune response to ASFV, we characterized the variation in GLN protein profiles of pigs infected with E75 (high virulence) and E75CV (low virulence) at different times post-infection using a 2-DE proteomics approach. Our previous study \[[@CR16]\] allowed to verify homogeneity between animals and that no outlier there was among the pigs studied. In these conditions, the technical variation can be the dominate source of variation \[[@CR23]\]. To overcome the inherent experimental variations of this technique, we performed simultaneously four replicate (four gels) of each day and condition and more than 85% of the spots were common between gels. After image analysis and visual confirmation of gels, around 800 spots were detected. Paired analyses between infected and control groups detected 80, 94, 62 and 39 differently changed spots with E75CV1 attenuated strain at 1, 3, 7 and 31 dpi respectively, corresponding to 42, 72, 53 and 33 different proteins. With E75 virulent isolate 57, 83 and 34 spots result differentially expressed at 1, 3 years, 7 dpi, corresponding to 33, 60 and 24 different proteins. In some cases, multiple spots were unambiguously identified as the same protein, it could arrive due to post-translational modification (crucial in the control of numerous regulatory pathways, degradation of proteins, biochemical alterations or pathogenesis), different isoforms derived from different genes of a multigen family, proteolytic damage or chemical modification of protein during sample preparation.

Differences in protein profiles were not only observed between virulent and attenuated ASFV strains, but also were shown between the different times post-infection tested. The most dramatic changes found affected lymph nodes from pigs infected with E75 at day 7pi, coinciding with the late phase of the E75 lethal virus infection, probably reflects the massive tissue destruction observed at this time post-infection, with only a few intact cells being present, mostly corresponding to infiltrates of ASFV-infected macrophages \[[@CR16]\]. GLNs from day 7 E75-infected pigs showed most proteins downregulated while infection with the attenuated E75CV1 virus upregulates a larger number of proteins than the virulent E75 strain at days 1, 3 and 7 pi, respectively (Table [1](#Tab1){ref-type="table"}). As expected, there are a considerable number of spots in common that change after infection with the two isolates (36, 62 and 23 at 1, 3 and 7 dpi respectively), while the rest became altered only during the infection with one of the isolates (Additional files [1](#MOESM1){ref-type="media"}, [2](#MOESM2){ref-type="media"}, [3](#MOESM3){ref-type="media"}, [4](#MOESM4){ref-type="media"} show the changes of expression of all proteins altered after infection and additional MS/MS information is available in Ref. \[[@CR24]\]). The proteins with the largest change in fold change are shown in Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}. Similarly, the expression of some proteins became apparent at specific times post-infection, while others were affected throughout the infection. As good examples, albumin and cytoskeletal proteins such as actin-like proteins were commonly affected by both ASFV strains, while many other proteins were differentially affected, such as heat shock protein B1 (HSPB1), involved in stabilizing actin filaments after stress, that results up-regulated exclusively at 1 dpi with E75CV1 \[[@CR25]\]. Of special interest were the proteins differentially regulated after the infection with the E75CV1 attenuated strain, reflecting changes in the immune system. Interestingly, some of these proteins became upregulated as soon as day 1 pi with E75CV1 (Additional file [1](#MOESM1){ref-type="media"}), including proteasome activator complex (PSME 1 and 2). Two proteins were inversely regulated after infection with the attenuated E75CV1 strain: HSPA1B and vimentin. While HPSA1B showed a downregulation, vimentin was upregulated at day 1 pi. Other proteins specifically upregulated at day 1 pi with E75CV1 were HSPB1, enolase or lymphocyte cytosolic protein 1 (LCP-1) (Additional file [1](#MOESM1){ref-type="media"}). As expected, the early events described at day 1 pi with E75CV1, correlate with the profile of upregulated proteins specifically found by day 31 pi and related with the immune response (Additional file [4](#MOESM4){ref-type="media"}), including immunoglobulin component fractions, such as IGKC and IGHG3, or components of the proteasome such as PMSA1 and PMSA6. The up-regulation of retinol-binding protein 4 (responsible for retinol transport), galactose mutarotase or calreticulin are also of interest.Table 1**Number of regulated spots in porcine lymph node at different times post-infection**1 dpi3 dpi7 dpi31 dpiE75CV1/control (attenuated)51 ↑29 ↓49 ↑45 ↓28 ↑34 ↓35 ↑4 ↓E75/control (virulent)32 ↑25 ↓30 ↑53 ↓1 ↑33 ↓---- Table 2**The top proteins with the largest change in expression in response to ASFV infection (1 dpi)**Attenuated-controlID SSPIDGen nameProtein namep*I*Mw (kDa)% coverageFold change*p* value5605F1RUN2ALBSerum albumin Sus scrofa5.9871.601934.70.0006605P02543VIMVimentin Sus scrofa5.0653.706327.50.0011307Q6QAQ1ACTBActin.cytoplasmic 1 Sus scrofa5.2942.119110.00026718P02554TUBBTubulin beta chain Sus scrofa4.7850.301710.10.00248411I7GKE9EEF2Similar to human eukaryotic translation elongation factor Macaca fascicularis5.9336.4216.70.0024807F1RMN7HPXHemopexin Sus scrofa6.5952.10214.50.00038315F1RS36HSPA578 kDaglucose-regulated protein Sus scrofa5.2170.3244.20.01758219I3L816HNRNPH1Heterogeneous nuclear ribonucleoprotein H Sus scrofa6.4446.6343.80.00148107K7EJP1ATP5A1ATP synthase subunit alpha.mitochondrial Homo sapiens5.5115.40293.50.00479602I3LK59ENOEnolase Sus scrofa8.9338.20293.40.00054806Q6S4N2HSPA1BHeat shock 70 kDa protein 1B Sus scrofa5.670.3018− 23.109508I3LEC2PCBP1Poly(rC)-binding protein 1 Sus scrofa6.6637.939− 150.00017420F1RKU0IDH3AIsocitrate dehydrogenase \[NAD\] subuni talpha, mitochondrial Sus scrofa6.7240.124− 100.0105407F1M0S3TPM2Tropomyosin beta chain Rattus norvegicus5.1931.138− 9.60.0003502C9J9K3RPSA40S ribosomal protein SA Homo sapiens5.153062− 8.60.0001302P62258YWHAE14-3-3 protein epsilon Homo sapiens4.7929.244− 7.50.00239804P09571TFSerotransferrin Sus scrofa6.9378.9036− 6.90.00139401P00355GAPDHGlyceraldehyde-3-phosphate dehydrogenase Sus scrofa8.5136.134− 5.70.001205F2Z558YWHAZ14-3-3 protein zeta Sus scrofa4.7728.2042− 5.40.00329107F1S3U9PRDX1Peroxiredoxin 1 Sus scrofa8.6722.144− 5.10.0052Virulent-controlID SSPIDGen nameProtein namep*I*Mw (kDa)% coverageFold change*p* value4107F1RUN2ALBSerum albumin Sus scrofa5.9871.60513.40.00126718P02554TUBBTubulin beta chain Susscrofa4.7850.301711.30.00035411F1RPH0PGK1Phosphoglycerate kinase Sus scrofa6.3243.4307.30.00098214D0G7F6TPI1Triosephosphate isomerase Sus scrofa6.5423.90896.50.0018411I7GKE9EEF2Similar to human eukaryotic translation elongation factor Macaca fascicularis5.9336.4216.50.00234308B6VNT8ACTC1Alpha actin 1 Sus scrofa5.2342.3850.00058107K7EJP1ATP5A1ATP synthase subunit alpha.mitochondrial Homo sapiens5.5115.40293.50.00028219I3L816HNRNPH1Heterogeneous nuclear ribonucleoprotein H Sus scrofa6.4446.6343.40.00081410Q9N0Y9\|TMOD3Ubiquitous tropomodulin U-Tmod Sus scrofa4.9839.7312.40.00027504F1SVB0CAPGMacrophage-capping protein Sus scrofa5.8839.2232.30.00229107F1S3U9PRDX1Peroxiredoxin 1 Sus scrofa8.6722.144− 6.10.0009302P62258YWHAE14-3-3 protein epsilon Homo sapiens4.7929.244− 13.60.00278806P09571TFSerotransferrin Sus scrofa6.9378.932− 11.70.0001301Q5ISS9YWHAQ14-3-3 protein theta isoform Sus scrofa4.729.2049− 11.40.00027715F1RFN9FSCN1Fascin Sus scrofa6.0455.2026− 9.80.0018404A2A6G8Lasp1LIM and SH3 domain protein 1 Mus musculus9.1412.150− 7.50.00048510I3LDC7\|IDH1Isocitrate dehydrogenase \[NADP\] (Fragment) Sus scrofa7.6448.724− 70.0011407F1M0S3TPM2Tropomyosin beta chain Rattus norvegicus5.1931.138− 5.20.0007502C9J9K3RPSA40S ribosomal protein SA Homo sapiens5.153062− 4.80.00025113Q08024CBFBCore-binding factor subunit beta Mus musculus5.5922.231− 4.40.0008 Table 3**The top proteins with the largest change in expression in response to ASFV infection (3 dpi)**Attenuated-controlID SSPIDGen nameProtein namep*I*Mw (kDa)% coverageFold change*p* value7226O15144ARPC2Actin-related protein 2/3 complex subunit 2 Homo sapiens6.8434.44513.10.00175435P50395GDI2Rab GDP dissociation inhibitor beta Sus scrofa6.3150.704912.40.00771427Q0QEN7ATP5BATP synthase subunit beta Sus scrofa4.99475810.70.01211133P20700LMNB1Lamin-B1 Homo sapiens5.1166.40148.50.01033625P11142HSP7CHeat shock cognate 71 kDa protein Homo sapiens5.3770.80278.40.00528533Q6MZU6IGHMIgG heavy chain Sus scrofa6.8252.90256.10.02478321B1ALA9PRPS1Phosphoribosyl pyrophosphate synthetase 1 Rattus norvegicus7.6224.40375.60.00032322P04899GNA12Guanine nucleotide-binding protein G(i) subunit alpha-2 Sus scrofa5.3541.00525.40.01222548P54920NAPAAlpha-soluble NSF attachment protein Homo sapiens5.2333.66655.20.00216128Q8MJ14GPX1Glutathione peroxidase 1 Sus scrofa6.7322.40225.10.00132026O89052TUBA1BAlpha-tubulin Mus musculus4.851160− 34.80.00081021P08835ALBSerum albumin Sus scrofa6.0869.7018− 24.30.00002131P84856ACTBActin.cytoplasmic 1 Cercopithecus pygerythrus5.5540.421− 18.10.01044017P61981YWHAG14-3-3 protein gamma Homo sapiens4.828.3047− 17.30.02103017P63104YWHAZ14-3-3 protein zeta/delta Homo sapiens4.7327.9046− 16.50.00014135P00829ATPBATP synthase subunit beta.mitochondrial Bos taurus5.1556.229− 11.20.00434013P31946YWHAB14-3-3 protein beta/alpha Homo sapiens4.7628.2063− 8.90.00004234Q9MYP6HSD17B1417-beta-hydroxysteroid dehydrogenase 14 Bos taurus6.1928.407− 5.90.00708148P09571TFSerotransferrin Sus scrofa6.9376.903− 4.90.00151018Q2HJ57COTL1Coactosin-like protein Bos taurus5.116.0036− 4.60.0199Virulent-controlID SSPIDGen nameProtein namep*I*Mw (kDa)% coverageFold change*p* value5435P50395GDI2Rab GDP dissociation inhibitor beta Sus scrofa6.3150.704916.30.01085142P19133FTLFerritin light chain Sus scrofa5.828.703211.60.00017226O15144ARPC2Actin-related protein 2/3 complex subunit 2 Homo sapiens6.8434.4458.70.00361427Q0QEN7ATP5BATP synthase subunit beta Sus scrofa4.9947588.60.00001133P20700LMNB1Lamin-B1 Homo sapiens5.1166.40146.30.00047137P60900PSMA6Proteasome subunit alpha type-6 Homo sapiens6.3427.30265.10.00041640P01009SERPINA1Alpha-1-antitrypsin Sus scrofa5.5447.4114.20.00296332P56471IDH3AIsocitratedehydrogenase \[NAD\] subunitalpha Sus scrofa6.7240.10504.00.00031130P52552PRDX2Peroxiredoxin-2 Sus scrofa4.6614.10363.60.00001224P08758ANXA5Annexin A5 Homo sapiens4.9435.8593.20.00343123P84856ACTBActin.cytoplasmic 1 Cercopithecus pygerythrus5.5540.429− 35.60.00824017P61981YWHAG14-3-3 protein gamma Homo sapiens4.828.3047− 19.80.01901021P08835ALBSerumalbumin Sus scrofa6.0869.7018− 12.70.00002026O89052TUBA1BAlpha-tubulin Mus musculus4.851160− 11.90.00014013P31946YWHAB14-3-3 protein beta/alpha Homo sapiens4.7628.2063− 11.10.00001331Q9N0Y9TMOD3Tropomodulin 3 Sus scrofa4.9839.7021− 10.50.00514234Q9MYP6HSD17B1417-beta-hydroxysteroid dehydrogenase 14 Bos taurus6.1928.407− 9.80.00623017P63104YWHAZ14-3-3 protein zeta/delta Homo sapiens4.7327.9046− 7.30.0000515P13489RNH1Ribonuclease inhibitor Sus scrofa4.7650.7064− 5.70.01621018Q2HJ57COTL1Coactosin-like protein Bos taurus5.116.0036− 4.60.0160 Table 4**The top proteins with the largest change in expression in response to ASFV infection (7 dpi)**Attenuated-controlID SSPIDGen nameProtein namep*I*Mw (kDa)% coverageFold change*p* value1509Q0QEM6ATP5BATP synthase subunit beta Sus scrofa4.9947.107226.60.02361405F8VYX6TUBBTubulin beta chain Homo sapiens5.148.90379.10.02228512F1RFI1TUFMElongation factor Tu Sus scrofa6.7249.704660.00048606P01790IGHIg heavy chain V region Mus musculus8.0113.70245.70.02321612P02543VIMVimentin Sus scrofa5.0653.70574.50.00973319B4DWA6CAPZBHighly similar to F-actin capping protein subunit beta Homo sapiens5.7737.8314.104005Q2TBX5SSR4Translocon-associated protein subunit delta Bos taurus5.4919.00373.90.0957412Q9GKX6GALMAldose 1-epimerase Sus scrofa6.3138.00303.70.00448209B5APU7ARPC2Actin-related protein 2/3 complex subunit 2 Sus scrofa6.8434.3633.70.0257108D6RBM0HNRNPH1Heterogeneous nuclear ribonucleoprotein H Homo sapiens6.9724.2623.70.00333005B3KWQ3ACTGHighly similar to Actin. cytoplasmic 2 Homo sapiens5.228.5029− 120.00557309F1RUN2ALBSerum albumin Sus scrofa5.9871.6030− 50.00043720Q5T6W5HNRNPKHeterogeneous nuclear ribonucleoprotein K Homo sapiens5.4647.7041− 4.90.0181308A5D989EEF1DElongation factor 1-delta Bos taurus4.9431.227− 4.803723F1MUZ9HSPD160 kDa chaperonin Bos taurus5.7161.1042− 4.30.00173318P11493\|PPP2CBSerine/threonine-protein phosphatase 2A catalytic subunit beta isoform Homo sapiens5.4634.135− 3.20.0234112Q1W2K3PSMB10Proteasome subunit beta Sus scrofa6.0929.2023− 3.20.00042613F1RG16HNRNPFHeterogeneous nuclear ribonucleoprotein F Sus scrofa5.3245.9042− 3.10.0452305I3L813PCNAProliferating cell nuclear antigen Sus scrofa4.5729.163− 2.90.0052309G7P8A3EGM_15385Serine/threonine-protein phosphatase Macaca fascicularis5.5533.946− 2.40.0003Virulent-controlID SSPIDGen nameProtein namep*I*Mw (Kda)% coverageFold change*p* value3516F1MRD0ACTBActin.cytoplasmic 1.Bos taurus5.1642.20386.10.02557309F1RUN2ALBSerumalbumin Sus scrofa5.9871.6030− 260.0113005B3KWQ3ACTGHighly similar to Actin. cytoplasmic 2 Homo sapiens5.228.5029− 240.02146417Q8IY98ACTR2Actin-related protein 2 Homo sapiens5.7739.9043− 6.40.00046313O88550CASP7Caspase 7 Rattus norvegicus5.5334.917− 5.50.01252012Q0IIA3SRISorcin Bos taurus5.1120.6020− 4.70.0149012Q9BGI4PRDX1Peroxiredoxin 1 Bos taurus8.8122.440− 4.60.00133314Q15181PPA1Inorganic pyrophosphatase Homo sapiens5.5433.141− 4.40.03742613F1RG16HNRNPFHeterogeneous nuclear ribonucleoprotein F Sus scrofa5.3245.9042− 4.30.0357207P61981YWHAG14-3-3 protein gamma Homo sapiens4.828.459− 3.40.0172309G7P8A3EGM_15385Serine/threonine-protein phosphatase Macaca fascicularis5.5533.946− 2.80.02236416Q99LC3NDUFA10NADH dehydrogenase \[ubiquinone\] 1 alpha subcomplex subunit 10. Mus musculus7.6340.8022− 2.30.0272208F2Z5C1ANXA5Annexin Sus scrofa4.9533.259− 2.10.0313305I3L813PCNAProliferating cell nuclear antigen Sus scrofa4.5729.163− 20.04012108F1SQW8ARHGDIBRho protein dissociation inhibitor homolog Sus scrofa5.0822.9055− 1.80.047306F1M0S3TPM2Tropomyosin beta chain Rattus norvegicus5.1931.140− 1.80.01557213K7D9V9HNRNPH3Heteroproteinous nuclear ribonucleoprotein H3 Pan troglodytes6.3635.268− 1.70.0419 Table 5**The top proteins with the largest change in expression in response to E75CV1 infection (31 dpi)**Attenuated-controlID SSPIDGen nameProtein namep*I*Mw (Kda)% coverageFold change*p* value4611Q4V7C7ACTR3Actin-related protein 3 homolog Rattus norvegicus5.6147.63210.10.00017219Q45FY6HPRT1Hypoxanthine--guanine phosphoribosyl transferase Sus scrofa6.324.806160.03831903A0A024R972LAMC1Laminin. gamma 1.isoform CRA_a Homo sapiens4.9417.90115.80.01897518P08835ALBAlbumin Sus scrofa5.9271.40374.80.0245513P00348HADHHydroxyacyl-coenzyme A dehydrogenase Sus scrofa9.0234.20323.80.02553211Q06AS6GNAI2Guanine nucleotide binding protein. alpha inhibiting activity polypeptide 2 Sus scrofa5.3541643.20.00358412P60901PSMA6Proteasome subunit alpha type-6 Rattus norvegicus6.3427.80512.50.01933410A0PA01SERPINB9Serpin peptidase inhibitor.clade B (ovalbumin).member 9 Sus scrofa5.3742.8612.40.01377212P04431IGKCImmunoglobulin kappa light chain Sus scrofa8.6512.20392.40.00812514P60953CDC42Chain B. Structure Of The Complex Between Dock9 and Cdc42. Homo sapiens6.321.50452.30.00197220P31943HNRNPHHeterogeneous nuclear ribonucleoprotein H Homo sapiens5.8949.50362.20.0276112P01860IGHG3Ig gamma 3 chain constant region. Sus scrofa7.2536.50282.20.00555119P80031GSTP1Glutathione S-transferase P1 Sus scrofa8.0723.7462.10.00897214Q9GKX6GALMGalactose mutarotase Sus scrofa6.3138.00441.90.0197614P52193CALRCalreticulin Bos taurus4.3146.50461.80.03347514P01834IGKCIg kappa light chain Sus scrofa8.6512.10411.80.00615118P27485RBP4Retinol-binding protein 4 Sus scrofa5.4123.4191.80.02051711P08670VIMVimentin Homo sapiens5.0353.758− 3.30.01098213B8XSK0CPNE1Copine 1 Sus scrofa5.4359.626− 2.60.00941611Q5S1U1HSPB1Heat shock protein beta-1 Sus scrofa6.2322.9016− 2.30.0064
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Bioinformatic tools were employed to biologically interpret the data set of protein obtained from 2-DE analysis, with the aim of gaining an insight into biological functions and pathways associated with the proteome response of porcine GLN to ASFV, as well as to discover differences in processes that occur after infection with each one of the ASFV-strains. Therefore, we have analyzed our data set using IPA, focused on cell functions and on canonical pathways, so-called because they contain well-established knowledge about specific relationships between groups of proteins. Differentially expressed proteins were involved in different aspects of the host--pathogen interaction (Additional files [5](#MOESM5){ref-type="media"}, [6](#MOESM6){ref-type="media"}, [7](#MOESM7){ref-type="media"}, [8](#MOESM8){ref-type="media"}, [9](#MOESM9){ref-type="media"}, [10](#MOESM10){ref-type="media"}, [11](#MOESM11){ref-type="media"}). With respect to functions, inflammatory and immunological disease were functions altered by both virus, but a greater number of proteins involved in these functions were differentially expressed after E75CV1 than E75 infection, at 1 dpi. Thus, we have found the up-regulation of proteins such as: HSPA5 and HSPB1, LCP1, vimentin, C reactive protein or hemopexin, a protein that positively regulates the interferon-gamma-mediated signaling pathway \[[@CR26]\]. Accordingly, our previous qPCR results \[[@CR16]\] showed an over-expression of interferon-gamma after infection with E75CV1 but not due to E75 infection, at 1 dpi. Conversely, GLNs from E75-infected pigs showed, at day 1 pi, the specific downregulation of SERPINA3, an acute phase protein that is induced during inflammation \[[@CR27]\] or vitamin D-binding protein (implicated in macrophage activation and inflammation) \[[@CR28]\], most probably contributing to a delayed inflammatory response to the virulent isolate.

Figure [1](#Fig1){ref-type="fig"} also included other functions (derived from the Ingenuity Pathways Analysis) significantly altered at early times after infection with both virus strains, e.g. those associated to free radical scavenging, cell death and cell-to-cell signaling and interaction, while cellular assembly and organization or cellular functions showed fewer modifications. Nevertheless, by day 7 pi with E75CV1, coinciding with the recovery of the infected pigs \[[@CR16]\], these latter functions became more relevant. Conversely, GLN from E75-infected pigs by day 7 pi, showed protein profiles enriched in functions related to tissue destruction when compared to E75CV1; these were mainly associated with connective tissue disorders, skeletal and muscular disorders or with organismal injury and abnormalities. Some of these abnormalities became evident as early as at day 3 pi, coinciding with the ASFV replication in the GLN \[[@CR16]\].Figure 1**Enriched functions associated with the response of porcine lymph node to ASFV during infection.** The analysis is derived from the Ingenuity Pathways Analysis.

The association of the proteins significantly affected by ASFV infection with canonical pathways is shown in Table [6](#Tab6){ref-type="table"}. As expected, the remodelling of epithelial adherent junction pathways was enriched for both viruses. In this canonical pathway, several members of the actin family participate, shown in here as differentially regulated. Also, clathrin-mediated endocytosis signaling pathways, involving molecules such as actin, heat shock proteins, serpin or transferrin, were regulated at all times post-infection with the exception of day 1 pi with E75CV1. One of the most remarkable and novel observations of our work affects the 14-3-3 mediated signaling, inhibited by both isolates at 1 and 3 dpi. It is also worth highlighting the differential regulation of Rho GTPases in GLNs from E75CV1 infected pigs between days 1 and 7, coinciding with the induction of innate immunity and the resolution of the subclinical ASFV infection \[[@CR29]\]. Regarding pathways regulated by only one virus, or in some cases at only times post-infection, is worthy to mention the G2/M DNA damage checkpoint regulation, involving the different 14.3.3 isoforms which we have been found downregulated after infection.Table 6**Analysis of the canonical pathways corresponding to the obtained data set**14-3-3-mediated signalingRemodeling of epithelial adherens junctionsClathrin-mediated endocytosis signalingSignaling by rho family GTPasesRhoGDI signalingEpithelial adherens junction signalingRegulation of actin-based motility by rhoCell Cycle: G2/M DNA damage checkpoint regulationMechanisms of viral exit from host cellsDeath receptor signalingVirus entry via endocytic pathwaysMyc mediated apoptosis signalingE75CV1 (dpi) 1XX----X--XX-------- 3XXX--X----X-------- 7--XXXXX------------ 31--XXXX--X----------E75 (dpi) 1XXX----X----X--X-- 3XXX----X--X------X 7--XX--XX------X----The analysis is derived from the Ingenuity Pathways Analysis (*p* \< 0.05).X: affected by ASFV infection; --: no affected by ASFV infection.

Discussion {#Sec10}
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Proteome approaches are being increasingly used in many different systems to investigate host--microbe interactions and it has provided important information about the protein profile of cells infected with ASFV \[[@CR10], [@CR17]\]. The results presented here could complement the aforementioned ones since they have been performed with infected pig tissue. In this context, in vivo models could help to reflect the multiple events undergone by the host upon pathogen infection. Here, we applied a proteomics approach, based on 2-DE coupled to an in vivo experiment, to obtain new insights about the differential responses triggered by attenuated and virulent homologous ASFV strains. Lymphnodes are complex tissues composed by different cell types and, despite ASFV main targets are the macrophages, it is known that the effect of virus infection is not only restricted to the infected cell but also to the cascade of events it provokes the massive apoptosis induced in surrounding non-infected lymphocytes, this being a key event for ASF pathogenesis, responsible for lymphoid organ impairment in acute ASFV infection \[[@CR30]\]. Besides, the lesions found in ours previous manuscript \[[@CR16]\] after necropsy together with a comparative transcription profile of key immune mediators that were differentially modulated throughout the infections point gastrohepatic lymph node as the organ of choice to improve our knowledge about of the differential porcine response against virulent or attenuated ASFV isolated, to further compare globally the immunopathogenesis of both virus strains.

Also, we used IPA in a hypothesis generative manner aiming to unmask the most relevant functions and pathways altered throughout the infection in GLN, one of its main target organs. Overall, the analysis shows that, together with pathways involved in host-immune responses, a significant number of other host functions are modified, demonstrating the complex host-virus interactions that occur in vivo. Despite the much lower ASFV load observed after infection with the attenuated ASFV strain \[[@CR16]\], major protein changes were detected early after infection with E75CV1, affecting not only the infected macrophages, but also surrounding cell-types in an indirect manner. Therefore, E75 and E75CV1 not only differed in the kinetics and in the clinical symptoms they provoke, but also in the pathways activated throughout the infections. The fewer number of proteins with virulent isolated at 1 dpi might help explain the failure of the innate immune system to detect and control the first rounds of E75-replication, thus allowing its rapid spread. Conversely, efficient regulation of the innate immune system became evident for E75CV1 as early as at 1 day pi. As example, the implication of the Rho GTPases signalling pathway by E75CV1 throughout infection, (Table [6](#Tab6){ref-type="table"}), perhaps confirming the relevance of this pathway in the innate immune system. Although the best-known function of this protein family is regulate and coordinates of actin and microtubule cytoskeletal dynamics and adhesion \[[@CR31]\], Rho GTPases regulate numerous basic cell functions including regulation of the signaling pathways and cellular responses that enable to phagocytes perform their innate immune functions to respond invading pathogens. Thus, they are key regulators of cell migration (through various cell-surface receptors as TLRs), reactive oxygen species (ROS) production by NADPH oxidase, phagocytosis and degranulations well as a essential, and perhaps unique, roles in the motile responses of leukocytes \[[@CR32]\]. Another studies also indicate that Rho GTPases provide alternative pathways to regulate NF-kB transcriptional activity in cells of the innate immune system \[[@CR32]\].

Several other proteins became differentially regulated by day 1 pi, as vimentin, enolase, HSPB1 or lymphocyte cytosolic protein 1 (LCP-1) (Additional file [1](#MOESM1){ref-type="media"}) from E75CV1-pigs. Vimentin has been described as an important molecule during ASFV morphogenesis by changing its localization to viral factories after in vitro infection \[[@CR33]\]. Thus, the upregulation of vimentin, at day 1 pi, might be an indirect effect provoked by E75CV1 infection on surrounding non-infected cells. Coincidently, vimentin and other proteins specifically upregulated at day 1 pi with E75CV1, such as HSPB1, enolase or LCP-1 (Additional file [1](#MOESM1){ref-type="media"}), share both their potential role in immune defense and their description as autoantigens in autoimmune disorders \[[@CR34]\]. In particular, the role of HSPs as immunogenic molecules able to activate T cells has been long known \[[@CR35]\] and several reports have shown that pretreatment with HSPs protects from autoimmune disease \[[@CR36]\]. Also, T-cell response to α-enolase could be involved in the pathogenesis of autoimmune diseases \[[@CR37]\]. We are currently trying to unmask the potential presence of auto-antibodies in pigs infected with E75CV1 by using sera from day 31 pi and the upregulated autoantigens found at day 1 pi. These markers might be of utility to diagnose chronic infections and/or to better understand ASFV pathogenesis during chronic infections.

Of particular interest could be the complex regulation found for several members of the heterogeneous nuclear ribonucleoprotein (hnRNP) complex, RNA-binding proteins involved in downstream gene regulation and G2/M DNA damage checkpoint regulation, apoptosis and immune regulation \[[@CR38]\]. hnRNPH1, a protein previously shown as being involved in virus replication \[[@CR39]\], was upregulated at day 1 pi with both viruses, overexpression that was maintained for the attenuated E75CV1 virus at day 3 and 7 pi. It has been reported that upregulation of hnRNPH causes a decrease in HIV virion production \[[@CR40]\]. Interestingly, it is worth noting the involvement of hnRNPH expression with TNF-α production \[[@CR41]\] and NF-κB activation, both proteins being involved in inflammation and immune response. In Hepatitis C virus infection, it has been proposed that hnRNP might limit the amount of viral RNA genomes available for incorporation into virus \[[@CR42]\]. These changes in expression could be significant and add information to the only described interaction between the ASFV p30 antigen and hnRNPK in Vero infected cells \[[@CR43]\]. The authors suggest that the interaction hnRNPK-p30 could contribute to the host cell shut-off and represent a possible additional mechanism by which ASFV down-regulates host cell mRNA translation.

Together with pathways involved in immune responses, it is worth highlighting, the pathways involved in cytoskeletal and epithelial adherent junction remodeling (Table [6](#Tab6){ref-type="table"}), reflecting the use that ASFV makes of cytoskeleton from virus entry to virus morphogenesis and cell egress \[[@CR9], [@CR44]\]. This result perfectly correlates with the function that this pathway plays during ASFV entry in pig cells \[[@CR45]\], involving molecules such as actin, heat shock proteins, serpin or transferrin, which have been found altered in our study. Similarly, the clathrin-mediated endocytosis pathways here highlighted, have already been described as essential for ASFV entry in susceptible cells \[[@CR45]\], giving consistency and validity to our results. Clathrin-mediated endocytosis, a strategy used by many viruses for cell entry \[[@CR46]\], is commonly activated during both attenuated and virulent ASFV infection (Table [6](#Tab6){ref-type="table"}) from day 1 pi with E75 and from day 3 pi with the E75CV1 strain, coinciding with the differential kinetics of ASFV in vivo replication observed for both strains \[[@CR16]\]. The differential expression of several other proteins also involved in cytoskeleton formation it is worthy to be discussed. Thereby, the Rho GTPase family is also involved in the regulation of microtubules during dynein-mediated capsid transport of herpes virus associated Kaposi's sarcoma \[[@CR47]\], a pathway also required for ASFV entry, morphogenesis and exit from the infected cells \[[@CR31], [@CR44]\]. The inhibition of RhoGTPases by RhoGDI by attenuated isolate might have a negative effect in all these processes thus impairing the in vivo transmission of E75CV1. Conversely, the down-expression of RhoGDI at 7 dpi, might contribute to the successful systemic dissemination of E75. Also, the results observed with RP/EB microtubule-associated protein (which negatively regulates microtubule formation) point in this direction. Thus, interestingly, in our study this protein is down-regulated at 1 dpi with both virus (which would facilitate the formation of the microtubules and therefore traffic virus at the onset of infection) but over-expressed to 3 dpi only with attenuated isolate (inhibiting the formation of the microtubules and thus the transport of the attenuated isolate).

A chapter apart deserves discussing the sub-expression found at early times post-infection (day 1 and 3 pi) with both viruses, of several of the 7 isoforms of 14-3-3 protein, a novel finding for ASFV. 14-3-3 interactome studies have demonstrated that 14-3-3 proteins participate in many events associated with infection in other viruses \[[@CR48]\], mainly activated by dsRNA. The downregulation observed for both E75CV1 and E75 in vivo might reflect the need of ASFV to evade the innate immune responses triggered by 14-3-3, including the activation of TNF and NFκB signalling or any other antimicrobial responses triggered by activating the TLR-14-3-3 pathways \[[@CR49]\]. While 14-3-3 has been strongly associated with the innate immunity activated in response to dsRNA \[[@CR50]\], its negative effect on virus morphogenesis \[[@CR51]\], and ASFV-exit from the cell, \[[@CR52]\], have been also described. On the other hand, an important function of 14-3-3 proteins is to inhibit apoptosis \[[@CR53]\] and downregulation of 14-3-3 might also have a direct effect on the G2/M DNA damage checkpoint regulation \[[@CR54]\], a pathway that prevents cells with damaged DNA entering the M phase of cell division before repairing. So, a defective G2/M checkpoint leads DNA damaged cells to apoptosis \[[@CR55]\]. Curiously enough, E75CV1 downregulates the G2/M cell cycle control checkpoint both at day 1 and 3 pi, while E75 does it at day 3 pi (Table [6](#Tab6){ref-type="table"}) as described for other viruses \[[@CR56]\]. The concomitant downregulation of the G2/M DNA damage checkpoint and 14-3-3 observed might contribute to differentially activate the apoptosis of the infected cells, perhaps contributing to the deficient in vivo dissemination of E75CV1 \[[@CR7]\]. All together, these results seem to reflect a very complex regulation of apoptosis during ASFV infection, as has been previously postulated \[[@CR57]\]. These results complement previous work demonstrating the effect of DNA damage and apoptosis in ASFV-in vitro replication \[[@CR58]\], confirming the role that 14-3-3 play during apoptosis inhibition \[[@CR53]\], as has been demonstrated for other viruses \[[@CR59]\]. Studies to confirm the relevance of 14-3-3 in this inhibition might help to design novel antiviral strategies.

The last part of the discussion will be dedicated to the results obtained with samples harvested at day 31 after the infection with E75CV1, that might be very useful to understand the intrinsic mechanisms involved in protection against E75-virulent challenge. As expected, the proteomic analysis performed with these samples seem to confirm the key relevance that both antibodies \[[@CR4]\] and CD8 T-cells \[[@CR15], [@CR60]\], play in protection against ASFV. The immunoglobulin (Ig) isoforms detected could play a dual role participating either in ASFV-antibody mediated protection \[[@CR4]\], or also in the formation of immune complexes found in chronically ASFV infected pigs \[[@CR15]\]. PMSA1 and PMS6 are involved in swine leukocyte antigen class I (SLAI) presentation and CD8-T cell induction but also have endoribonuclease activity, playing important defensive roles in response to external stimuli \[[@CR61]\]. The up-regulation of other proteins with implication in the antigenic presentation, such as retinol-binding protein 4 (responsible for retinol transport) and galactose mutarotase (GALM) are also of interest. Retinol is a potent regulator of B-cell receptor function and B-cell activation \[[@CR62]\] and regulates GALM gene expression, which could have an important role in cell adhesion and antigen presentation \[[@CR63]\]. Other components of the B cell response were upregulated, including members of Ig family, proteins implicated in antigenic processing and SLAI antigen presentation (as proteasome subunits), calreticulin or serpin. Calreticulin (CRT) is a Ca2^+^-binding protein involved in more than 40 functions, including the unfolded protein response (UPR) and antigen presentation. Interestingly, CRT has been found upregulated in vitro as part of endoplasmic reticulum (ER) stress and the UPR provoked by ASFV in infected cell \[[@CR64]\]. UPR is a antiviral mechanism, against which many viruses develop multiple strategies \[[@CR65]\] and on the other hand, CRT transport antigens to the ER, facilitating antigen presentation in association with the major histocompatibility complex class I (MHC-I) molecules to elicit peptide-specific CD8^+^ T cell responses \[[@CR66]\]. In accordance with the latter, several other proteins involved in antigen presentation and T-cell activation have been found up-regulated at day 31 pi with E75CV1, including SERPINB9 and proteasomal subunits. Serpin B anti-proteases have been defined as regulators of the immune response up-regulated during several virus infections, including HIV \[[@CR67]\] and Epstein--Barr virus infection \[[@CR68]\]. SERPINB9 has been shown to be involved in protection of antigen presenting cells, enhancing T cell activation and immune response \[[@CR68]\], including in IFN-γ production and antiviral cytopathic responses \[[@CR69]\] and survival of CD8^+^ memory T cells \[[@CR70]\]. The proteomic data obtained with samples from E75CV1-recoverd pigs (31 dpi) perfectly fits with the increasing evidence that Th1 and specific CD8 T-cells play in protection \[[@CR3]\], including our previous data using this same ASFV-infection model \[[@CR16]\]. Altogether, our results could indicate that the over-expression of CRT, SERPINB9 and subunits from the proteasome reflect the relevance that SLAI presentation and CD8 T-cell activation play during ASFV infection, opening new avenues to fight the disease. Interestingly, these three components have already been used as genetic adjuvants to improve the specific immunity against several pathogens \[[@CR68]\]. We are currently extending our studies to the field of ASFV vaccinology. Thus, today we know that targeting antigens to the proteasome improves the protection against ASFV even in the absence of antibodies \[[@CR14], [@CR60]\]. The knowledge gained here opens new avenues to improve these strategies in the near future.

In conclusion, the data presented here are the first to compare kinetics of protein expression profiles from pigs infected by homologous virulent or attenuated strains of ASFV, through a proteomics approach coupled with a large-scale in vivo infection, in order to allow the generation of advances in our understanding about the pig immune response to virus and pathogenesis of ASF over time. Our results confirm a differential interaction with the immune system for both viruses. Thus, GLN from E75CV1 infected pigs showed the largest number of differentially upregulated proteins as early as 1 dpi, many of them involved in the activation of different innate immune pathways, including autoantigens. In addition to a lower replication efficiency at early time post-infection by attenuated isolated, the induction of specific antibody and T-cell responses at 31 dpi, were observed, once E75CV1 has been cleared. We believe that the increased information yielded by this global approach could improve our knowledge about the major point underlying host--pathogen interactions and might be the important for the development of an efficacious ASF vaccine.
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